HLA001

Raji HLA Panel Cell Lines

Properties

• biological source: human lymph
• growth mode: suspension
• morphology: lymphoblast
• shipped in: dry ice
• storage temp.: −196°C

Description

General description

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 85011429.

This product is a panel of nine (9) genetically modified cell lines targeting MHC Class I HLA molecules in a Raji lymphoblast parental cell line background.  The full HLA panel consists of a Beta-2 microglobulin (β2M) knockout cell line and an additional eight (8) monoallelic HLA expression cell lines.  

CompoZr^® Zinc Finger Nuclease (ZFN) technology was used to generate the β2M knockout cell line, which does not express endogenous cell surface MHC Class I HLA molecules (HLA-A or HLA-B) as measured by fluorescence-activated cell sorting (FACS).  

MISSION^® lentivirus was used to generate the eight (8) monoallelic HLA cell lines, which express individual HLA-A or HLA-B subtypes on the cell surface via a β2M:HLA fusion protein as described in Nature Biotechnology 35, 765-772, (2017) and as demonstrated via FACS analysis.    

Cell Line Description

Established in 1963 from Burkitt′s lymphoma in an 11 year old male. Growth is in the form of single cells without attachment and as macroscopically visible clumps containing many hundreds of cells. Resistant to VSV. This cell line carries the latent Epstein-Barr Virus (EBV) genome and is positive for EBNA. Raji is sometimes referred to as a ′non-producer′; the EBV genome carries deletions attributed to preventing the formation of virus particles. Ethnicity: Black

Features and Benefits

Unlike wild type Raji cells, which express multiple HLA subtypes, the Raji HLA panel cell lines express individual MHC Class I HLA subtypes. These monoallelic HLA cell lines can be used to study peptide binding and presentation in the context of individual HLA subtypes. The panel can also be used to develop cell-based assays to evaluate candidate cancer immunotherapies and identify tumor-specific neoantigens.

Components

HLA001A-1VL: Raji B2M KO Cells
HLA001B-1VL: Raji HLA-A*02:01 Cells
HLA001C-1VL: Raji HLA-A*01:01 Cells
HLA001D-1VL: Raji HLA-A*03:01 Cells
HLA001E-1VL: Raji HLA-A*11:01 Cells
HLA001F-1VL: Raji HLA-A*24:02 Cells
HLA001G-1VL: Raji HLA-B*15:10 Cells
HLA001H-1VL: Raji HLA-B*07:02 Cells
HLA001K-1VL: Raji HLA-B*40:01 Cells

Quality

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.

Legal Information

MISSION Use Licenses Agreement

ZFN Use Licenses Agreement

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Safety Information

• Storage Class: 6.2 - Infectious substances
• wgk_germany: WGK 2